Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer

Oncogene, Published online: 10 February 2020; doi:10.1038/s41388-020-1202-yPreclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer

Source: Oncogene - February 9, 2020 Category: Cancer & Oncology Authors: Sean P. Kennedy Michael O ’Neill Darren Cunningham Patrick G. Morris Sinead Toomey Carmen Blanco-Aparicio Sonia Martinez Joaquin Pastor Alex J. Eustace Bryan T. Hennessy Source Type: research